Keros Therapeutics, Inc.‘s KROS board of administrators initiated a proper overview course of on Thursday to guage strategic alternate options, together with a sale.
“In step with our dedication to taking motion to boost stockholder worth, Keros’ board decided to undertake a overview of all strategic alternate options out there to the Firm,” mentioned Jean-Jacques Bienaimé, Lead Unbiased Director. “Through the pendency of the strategic overview course of, we stay centered on the execution of our technique.”
Keros intends to offer a preliminary replace relating to the standing of the method inside 60 days.
The corporate additionally adopted a limited-duration stockholder rights plan, efficient instantly. Traders have been quickly accumulating widespread inventory, together with a person investor with an 11.2% stake within the firm.
In March, Keros Therapeutics introduced preliminary topline outcomes from the Section 1 scientific trial of KER-065 in wholesome volunteers by the a number of ascending dose therapy interval (Day 85).
The corporate mentioned scientific knowledge from this trial and preclinical knowledge help KER-065’s therapeutic potential for Duchenne muscular dystrophy and different neuromuscular indications.
In its fourth-quarter earnings launch, the corporate reported that money and money equivalents as of Dec. 31, 2024, have been $559.9 million, and a $200 million upfront cost from the Takeda Settlement is predicted to offer a money runway into 2029.
Value Motion: KROS inventory is up 16.3% at $12.01 on the final examine Thursday.
Learn Subsequent:
Picture: Shutterstock
Market Information and Knowledge delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
